Semaglutide protects against diabetes‐associated cardiac inflammation via Sirt3‐dependent RKIP pathway
British Journal of Pharmacology · 2025
DOI: 10.1111/bph.17327 ↗At a glance
Journal article in British Journal of Pharmacology, 2025. Written by Kaibin Lin and 8 co-authors. Institution: Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China. Major MEDLINE topics: Glucagon-Like Peptide-1 Receptor Agonists, Diabetic Cardiomyopathies, Phosphatidylethanolamine Binding Protein, Myocardium. Cited 36 times so far (Crossref); 60 references. Funded by: National Natural Science Foundation of China, National Outstanding Youth Science Fund Project of National Natural Science Foundation of China.
Topics: Diabetes mellitus
Abstract (original language)
Background and Purpose Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) exert cardiovascular benefits in diabetic patients, but the underlying mechanisms remain incompletely understood. Semaglutide, a novel long‐acting GLP‐1RA, has shown a reduced risk of cardiovascular events. Based on these results, we investigated the therapeutic potential of semaglutide in diabetic cardiomyopathy and sought to elucidate the underlying mechanisms. Experimental Approach Mice with diabetes induced by high‐fat diet/streptozotocin were treated with semaglutide. The mechanisms underlying the cardioprotective effects of semaglutide were analysed using animal and cell experiments. Key Results In diabetic mice, semaglutide alleviated metabolic disorders, ameliorated myocardial fibrosis, improved cardiac function, antagonized oxidative stress and suppressed cardiomyocyte apoptosis. More significantly, semaglutide attenuated cardiac inflammation through restoring Raf kinase inhibitor protein (RKIP) expression and inhibiting downstream TANK‐binding kinase 1 (TBK1)‐NF‐κB pathway. Meanwhile, decreased RKIP expression and activated TBK1‐NF‐κB signalling pathway were also found in tissues from human diabetic hearts. RKIP deficiency exacerbated cardiac inflammation and offset the cardioprotective effect of semaglutide in diabetic mice. Moreover, semaglutide also restored the expression level of Sirtuin 3(Sirt3), which served as a modulator against cardiac inflammation by regulating RKIP‐dependent pathway. In diabetic mice, RKIP deficiency abolished the cardioprotective benefits conferred by the Sirt3 activator honokiol. We also found that cAMP/PKA signalling, rather than glucose lowering, contributed to the anti‐inflammatory effect of semaglutide through Sirt3‐dependent RKIP pathway. Conclusions and Implications Semaglutide exerted cardioprotective effects against diabetic heart failure by alleviating cardiac inflammation through Sirt3‐dependent RKIP signalling pathway.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China.
- Department of Cardiovascular Diseases, The Affiliated Hospital of Jiaxing University, Jiaxing, China.
- Department of Cardiovascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
- Heart Center, Shanghai Jiaotong University Affiliated Sixth People's Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
- CAS Key Laboratory of Nutrition, Metabolism and Food Safety, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China.
- School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Funding
- National Natural Science Foundation of China
- National Outstanding Youth Science Fund Project of National Natural Science Foundation of China
Cite
APA
Lin, K., Wang, A., Zhai, C., Zhao, Y., Hu, H., Huang, D., Zhai, Q., Yan, Y., & Ge, J. (2025). Semaglutide protects against diabetes‐associated cardiac inflammation via Sirt3‐dependent RKIP pathway. British Journal of Pharmacology. https://doi.org/10.1111/bph.17327
Vancouver
Lin K, Wang A, Zhai C, Zhao Y, Hu H, Huang D, et al. Semaglutide protects against diabetes‐associated cardiac inflammation via Sirt3‐dependent RKIP pathway. British Journal of Pharmacology. 2025. doi:10.1111/bph.17327
BibTeX
@article{Lin2025,
author = {Lin, Kaibin and Wang, Ai and Zhai, Changlin and Zhao, Yun and Hu, Huilin and Huang, Dong and Zhai, Qiwei and Yan, Yan and Ge, Junbo},
title = {Semaglutide protects against diabetes‐associated cardiac inflammation via Sirt3‐dependent RKIP pathway},
journal = {British Journal of Pharmacology},
year = {2025},
doi = {10.1111/bph.17327}
}
EUVIMED